Tilogotamab (GEN-1029) is an enhanced hexameric mixture of two agonistic antibodies that bind to distinct epitopes on death receptor type 5 (DR5), specifically activating it. This compound is utilized in the research of multiple myeloma (MM) [1].

Tilogotamab（20 μg/mL；24小时）展现出对原代多发性骨髓瘤（MM）细胞显著的细胞毒性[1]。该化合物是由两种带有E430G突变的Fc域的、对DR5具有特异性的非竞争性免疫球蛋白G1（IgG1）抗体组成，这种突变促使Fc区域能更强地相互作用，导致抗体六聚体的形成和随后的FcγR独立于DR5分子的聚集[1]。